The novel unimolecular pill amycretin combines a GLP-1 and an amylin agonist and led to weight loss of 13% at 12 weeks in a phase 1 trial that just concluded, the company said.
Higher time in optimal glycemic range was associated with reduced risk for preeclampsia and for birth weight larger than gestational age, new research found.